229 related articles for article (PubMed ID: 34112038)
1. Therapies in preclinical and clinical development for Angelman syndrome.
Markati T; Duis J; Servais L
Expert Opin Investig Drugs; 2021 Jul; 30(7):709-720. PubMed ID: 34112038
[No Abstract] [Full Text] [Related]
2. Cas9 gene therapy for Angelman syndrome traps Ube3a-ATS long non-coding RNA.
Wolter JM; Mao H; Fragola G; Simon JM; Krantz JL; Bazick HO; Oztemiz B; Stein JL; Zylka MJ
Nature; 2020 Nov; 587(7833):281-284. PubMed ID: 33087932
[TBL] [Abstract][Full Text] [Related]
3. Gene Therapy for Angelman Syndrome: Contemporary Approaches and Future Endeavors.
Tsagkaris C; Papakosta V; Miranda AV; Zacharopoulou L; Danilchenko V; Matiashova L; Dhar A
Curr Gene Ther; 2020; 19(6):359-366. PubMed ID: 31914913
[TBL] [Abstract][Full Text] [Related]
4. Towards a therapy for Angelman syndrome by targeting a long non-coding RNA.
Meng L; Ward AJ; Chun S; Bennett CF; Beaudet AL; Rigo F
Nature; 2015 Feb; 518(7539):409-12. PubMed ID: 25470045
[TBL] [Abstract][Full Text] [Related]
5. Potential therapeutic approaches for Angelman syndrome.
Bi X; Sun J; Ji AX; Baudry M
Expert Opin Ther Targets; 2016; 20(5):601-13. PubMed ID: 26558806
[TBL] [Abstract][Full Text] [Related]
6. CRISPR/Cas9 directed to the Ube3a antisense transcript improves Angelman syndrome phenotype in mice.
Schmid RS; Deng X; Panikker P; Msackyi M; Breton C; Wilson JM
J Clin Invest; 2021 Mar; 131(5):. PubMed ID: 33411694
[TBL] [Abstract][Full Text] [Related]
7. Angelman syndrome - insights into a rare neurogenetic disorder.
Buiting K; Williams C; Horsthemke B
Nat Rev Neurol; 2016 Oct; 12(10):584-93. PubMed ID: 27615419
[TBL] [Abstract][Full Text] [Related]
8. A high-fidelity RNA-targeting Cas13 restores paternal Ube3a expression and improves motor functions in Angelman syndrome mice.
Li J; Shen Z; Liu Y; Yan Z; Liu Y; Lin X; Tang J; Lv R; Geng G; Xiong ZQ; Zhou C; Yang H
Mol Ther; 2023 Jul; 31(7):2286-2295. PubMed ID: 36805082
[TBL] [Abstract][Full Text] [Related]
9. Transcriptional reprogramming restores UBE3A brain-wide and rescues behavioral phenotypes in an Angelman syndrome mouse model.
O'Geen H; Beitnere U; Garcia MS; Adhikari A; Cameron DL; Fenton TA; Copping NA; Deng P; Lock S; Halmai JANM; Villegas IJ; Liu J; Wang D; Fink KD; Silverman JL; Segal DJ
Mol Ther; 2023 Apr; 31(4):1088-1105. PubMed ID: 36641623
[TBL] [Abstract][Full Text] [Related]
10. Antisense oligonucleotide therapy rescues disturbed brain rhythms and sleep in juvenile and adult mouse models of Angelman syndrome.
Lee D; Chen W; Kaku HN; Zhuo X; Chao ES; Soriano A; Kuncheria A; Flores S; Kim JH; Rivera A; Rigo F; Jafar-Nejad P; Beaudet AL; Caudill MS; Xue M
Elife; 2023 Jan; 12():. PubMed ID: 36594817
[No Abstract] [Full Text] [Related]
11. An ASO therapy for Angelman syndrome that targets an evolutionarily conserved region at the start of the
Dindot SV; Christian S; Murphy WJ; Berent A; Panagoulias J; Schlafer A; Ballard J; Radeva K; Robinson R; Myers L; Jepp T; Shaheen H; Hillman P; Konganti K; Hillhouse A; Bredemeyer KR; Black L; Douville J; ;
Sci Transl Med; 2023 Mar; 15(688):eabf4077. PubMed ID: 36947593
[TBL] [Abstract][Full Text] [Related]
12. Ube3a-ATS is an atypical RNA polymerase II transcript that represses the paternal expression of Ube3a.
Meng L; Person RE; Beaudet AL
Hum Mol Genet; 2012 Jul; 21(13):3001-12. PubMed ID: 22493002
[TBL] [Abstract][Full Text] [Related]
13. Truncation of Ube3a-ATS unsilences paternal Ube3a and ameliorates behavioral defects in the Angelman syndrome mouse model.
Meng L; Person RE; Huang W; Zhu PJ; Costa-Mattioli M; Beaudet AL
PLoS Genet; 2013; 9(12):e1004039. PubMed ID: 24385930
[TBL] [Abstract][Full Text] [Related]
14. UBE3A reinstatement as a disease-modifying therapy for Angelman syndrome.
Elgersma Y; Sonzogni M
Dev Med Child Neurol; 2021 Jul; 63(7):802-807. PubMed ID: 33543479
[TBL] [Abstract][Full Text] [Related]
15. A bipartite boundary element restricts
Hsiao JS; Germain ND; Wilderman A; Stoddard C; Wojenski LA; Villafano GJ; Core L; Cotney J; Chamberlain SJ
Proc Natl Acad Sci U S A; 2019 Feb; 116(6):2181-2186. PubMed ID: 30674673
[TBL] [Abstract][Full Text] [Related]
16. Characterization and structure-activity relationships of indenoisoquinoline-derived topoisomerase I inhibitors in unsilencing the dormant
Lee HM; Clark EP; Kuijer MB; Cushman M; Pommier Y; Philpot BD
Mol Autism; 2018; 9():45. PubMed ID: 30140420
[TBL] [Abstract][Full Text] [Related]
17. Emerging Gene and Small Molecule Therapies for the Neurodevelopmental Disorder Angelman Syndrome.
Copping NA; McTighe SM; Fink KD; Silverman JL
Neurotherapeutics; 2021 Jul; 18(3):1535-1547. PubMed ID: 34528170
[TBL] [Abstract][Full Text] [Related]
18. Maternal disruption of Ube3a leads to increased expression of Ube3a-ATS in trans.
Landers M; Calciano MA; Colosi D; Glatt-Deeley H; Wagstaff J; Lalande M
Nucleic Acids Res; 2005; 33(13):3976-84. PubMed ID: 16027444
[TBL] [Abstract][Full Text] [Related]
19. Ube3a reinstatement identifies distinct developmental windows in a murine Angelman syndrome model.
Silva-Santos S; van Woerden GM; Bruinsma CF; Mientjes E; Jolfaei MA; Distel B; Kushner SA; Elgersma Y
J Clin Invest; 2015 May; 125(5):2069-76. PubMed ID: 25866966
[TBL] [Abstract][Full Text] [Related]
20. Topoisomerase inhibitors unsilence the dormant allele of Ube3a in neurons.
Huang HS; Allen JA; Mabb AM; King IF; Miriyala J; Taylor-Blake B; Sciaky N; Dutton JW; Lee HM; Chen X; Jin J; Bridges AS; Zylka MJ; Roth BL; Philpot BD
Nature; 2011 Dec; 481(7380):185-9. PubMed ID: 22190039
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
